Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Theriva Biologics Inc. (TOVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TOVX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.25% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.94M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 2 | Beta 0.78 | 52 Weeks Range 0.37 - 7.15 | Updated Date 08/15/2025 |
52 Weeks Range 0.37 - 7.15 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.22 |
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.47 | Actual -1.93 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.17% | Return on Equity (TTM) -154.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5288235 | Price to Sales(TTM) - |
Enterprise Value -5288235 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.72 | Shares Outstanding 9059230 | Shares Floating 9085037 |
Shares Outstanding 9059230 | Shares Floating 9085037 | ||
Percent Insiders 0.14 | Percent Institutions 11.82 |
Upturn AI SWOT
Theriva Biologics Inc.
Company Overview
History and Background
Theriva Biologics, Inc. (formerly Synthetic Biologics, Inc.) is a clinical-stage company focused on developing therapies to treat infectious diseases and cancer. Founded as Synthetic Biologics, the company rebranded to Theriva Biologics to reflect its evolving therapeutic focus.
Core Business Areas
- VCN-01: VCN-01, a oncolytic adenovirus, is the company's lead drug candidate currently in clinical development targeting solid tumors. It is designed to selectively replicate within and destroy cancer cells.
- SYN-004 (ribaxamase): Formerly known as SYN-004 (ribaxamase), this product candidate aimed to degrade certain intravenous beta-lactam antibiotics in the gastrointestinal (GI) tract to prevent Clostridium difficile-associated diarrhea (CDAD). Program was terminated.
Leadership and Structure
The company's leadership team includes experienced professionals in the fields of oncology and drug development. The specific organizational structure is available on their corporate website and SEC filings.
Top Products and Market Share
Key Offerings
- VCN-01: VCN-01 is Theriva Biologics' leading asset in development. It's an oncolytic adenovirus targeting solid tumors. Market share is currently 0%, as it is not yet approved for sale. Competitors include other oncolytic virus developers and companies developing standard cancer therapies.
- SYN-004 (ribaxamase): This product candidate was aimed to degrade certain intravenous beta-lactam antibiotics in the gastrointestinal (GI) tract to prevent Clostridium difficile-associated diarrhea (CDAD). Program was terminated.
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing market driven by increasing cancer incidence, advances in treatment options, and aging populations. Oncolytic virus therapies are an emerging area within oncology.
Positioning
Theriva Biologics is positioning itself as an innovator in the oncolytic virus therapy space. Its competitive advantage lies in its specific virus construct, and tumor-targeting mechanism. There are many other companies with similar cancer approaches.
Total Addressable Market (TAM)
The TAM for solid tumor therapies is estimated to be in the hundreds of billions of dollars globally. Theriva Biologics' TAM is a subset of this, representing the potential market for VCN-01 within specific tumor types. The size of Theriva Biologicsu2019s TAM is hard to determine as VCN-01 is still in the clinical trial phase.
Upturn SWOT Analysis
Strengths
- Novel oncolytic virus technology
- Experienced management team
- Clinical-stage product candidate
Weaknesses
- Limited financial resources
- Reliance on a single lead product candidate
- High regulatory risk associated with drug development
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
Threats
- Competition from established cancer therapies
- Regulatory setbacks
- Failure to secure funding
Competitors and Market Share
Key Competitors
- DNLI
- BNTX
- MRNA
Competitive Landscape
Theriva Biologics competes with established cancer therapies and other companies developing oncolytic viruses. Its competitive advantage hinges on the efficacy and safety of VCN-01.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on clinical trial progress and funding. The company's past performance will need to be obtained from SEC filings.
Future Projections: Future growth depends on successful clinical development of VCN-01 and securing partnerships or funding.
Recent Initiatives: Recent initiatives include advancing VCN-01 through clinical trials and exploring strategic collaborations.
Summary
Theriva Biologics is a clinical-stage biotech company with a focus on oncolytic virus therapies. The company's future hinges on the successful development of VCN-01, its lead product candidate. Limited financial resources and regulatory risks are key challenges. Positive clinical data and strategic partnerships could drive growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theriva Biologics Inc.
Exchange NYSE MKT | Headquaters Rockville, MD, United States | ||
IPO Launch date 2006-12-18 | CEO, CFO, Treasurer, Corporate Secretary & Director Mr. Steven A. Shallcross CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://therivabio.com |
Full time employees 20 | Website https://therivabio.com | ||
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.